Background:
Tectorigenin is a plant isoflavonoid originally isolated from the dried flower of Pueraria thomsonii Benth.
Tectorigenin is a plant isoflavonoid originally isolated from the dried flower of Pueraria thomsonii Benth. Palmitic acid (PA)-stimulated ROS production is abolished by treatment with Tectorigenin for HUVECs in a dose-dependent manner (0.1, 1, 10 μM). Treatment with Tectorigenin attenuates enhanced IKKβ phosphorylation and effectively blocks NF-κB activation by inhibition of p65 phosphorylation at concentrations ranging from 0.1 to 10 μM. Tectorigenin treatment also effectively inhibits PA-augmented TNF-α and IL-6 production in a concentration dependent manner[1]. The number of viable HepG2 cells treated by Tectorigenin decreases in a concentration- and time-dependent manner. When HepG2 cells are treated with Tectorigenin at 5, 10 and 20 mg/L for 24 h, the viability rate is 91%, 79% and 62%, respectively[2].
参考文献:
[1]. Wang Q, et al. Tectorigenin Attenuates Palmitate-Induced Endothelial Insulin Resistance via Targeting ROS-Associated Inflammation and IRS-1 Pathway. PLoS One. 2013 Jun 19;8(6):e66417.
[2]. Jiang CP, et al. Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells. World J Gastroenterol. 2012 Apr 21;18(15):1753-64.
动态评分
0.0